« Back
Home /
Eribulin (mesylate)

Eribulin (mesylate)

Item no.	HY-13442A-1mg
Manufacturer	MedChem Express
CASRN	441045-17-6
Amount	1 mg
Quantity options	100 mg 10 mg 1 mg 25 mg 500 ug 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	99.91
Dry ice	Yes
Citations	[1]Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7(7): p. 2003-11.\|[2]Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49(6): p. 1331-7.\|[3]Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71(2): p. 496-505.\|[4]Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174. Molecules. 2025 Feb 14.\|iScience. 6 September 2022, 105081.\|NPJ Breast Cancer. 2025 Feb 17;11(1):17.\|Res Sq. 2024 Sep 17.
Smiles	C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O.CS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	B1939 (mesylate),E7389 (mesylate),ER-086526 (mesylate)
Shipping Condition	Dry ice
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Microtubule/Tubulin
Shipping Temperature	Dry Ice
Storage Conditions	-80°C, protect from light, stored under nitrogen
Molecular Weight	826.00
Product Description	Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 100 mg/mL
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13442A-1mg-safety-datasheet.pdf